Literature DB >> 33230949

The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.

Brooklynn Venteicher1, Kasey Merklin1, Huy X Ngo2, Huan-Chieh Chien2, Keino Hutchinson3, Jerome Campbell1, Hannah Way1, Joseph Griffith1, Cesar Alvarado1, Surabhi Chandra4, Evan Hill5, Avner Schlessinger3, Allen A Thomas1.   

Abstract

The l-type amino acid transporter 1 (LAT1, SLC7A5) imports dietary amino acids and amino acid drugs (e. g., l-DOPA) into the brain, and plays a role in cancer metabolism. Though there have been numerous reports of LAT1-targeted amino acid-drug conjugates (prodrugs), identifying the structural determinants to enhance substrate activity has been challenging. In this work, we investigated the position and orientation of a carbonyl group in linking hydrophobic moieties including the anti-inflammatory drug ketoprofen to l-tyrosine and l-phenylalanine. We found that esters of meta-carboxyl l-phenylalanine had better LAT1 transport rates than the corresponding acylated l-tyrosine analogues. However, as the size of the hydrophobic moiety increased, we observed a decrease in LAT1 transport rate with a concomitant increase in potency of inhibition. Our results have important implications for designing amino acid prodrugs that target LAT1 at the blood-brain barrier or on cancer cells.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  amino acids; blood-brain barrier; drug delivery; membrane proteins; prodrugs

Mesh:

Substances:

Year:  2020        PMID: 33230949      PMCID: PMC7933125          DOI: 10.1002/cmdc.202000824

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  49 in total

1.  Large neutral amino acid transporter enables brain drug delivery via prodrugs.

Authors:  Mikko Gynther; Krista Laine; Jarmo Ropponen; Jukka Leppänen; Anne Mannila; Tapio Nevalainen; Jouko Savolainen; Tomi Järvinen; Jarkko Rautio
Journal:  J Med Chem       Date:  2008-01-25       Impact factor: 7.446

2.  Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.

Authors:  Henna Ylikangas; Lauri Peura; Kalle Malmioja; Jukka Leppänen; Krista Laine; Antti Poso; Maija Lahtela-Kakkonen; Jarkko Rautio
Journal:  Eur J Pharm Sci       Date:  2012-12-08       Impact factor: 4.384

3.  Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier.

Authors:  Y Kido; I Tamai; H Uchino; F Suzuki; Y Sai; A Tsuji
Journal:  J Pharm Pharmacol       Date:  2001-04       Impact factor: 3.765

4.  Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites.

Authors:  Alex R Maolanon; Rune Risgaard; Shuang-Yan Wang; Yoran Snoep; Athanasios Papangelis; Feng Yi; David Holley; Anne F Barslund; Niels Svenstrup; Kasper B Hansen; Rasmus P Clausen
Journal:  ACS Chem Neurosci       Date:  2017-05-30       Impact factor: 4.418

5.  Mechanism of substrate recognition and transport by an amino acid antiporter.

Authors:  Xiang Gao; Lijun Zhou; Xuyao Jiao; Feiran Lu; Chuangye Yan; Xin Zeng; Jiawei Wang; Yigong Shi
Journal:  Nature       Date:  2010-01-20       Impact factor: 49.962

6.  BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells.

Authors:  Chun Sung Kim; Seon-Ho Cho; Hong Sung Chun; Sook-Young Lee; Hitoshi Endou; Yoshikatsu Kanai; Do Kyung Kim
Journal:  Biol Pharm Bull       Date:  2008-06       Impact factor: 2.233

7.  The L-3,4-dihydroxyphenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino acid exchanger.

Authors:  Sónia Fraga; Maria Paula Serrão; Patrício Soares-da-Silva
Journal:  Eur J Pharmacol       Date:  2002-04-26       Impact factor: 4.432

8.  Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.

Authors:  Veronika Buxhofer-Ausch; Lena Secky; Katrin Wlcek; Martin Svoboda; Valentinos Kounnis; Evangelos Briasoulis; Andreas G Tzakos; Walter Jaeger; Theresia Thalhammer
Journal:  J Drug Deliv       Date:  2013-02-03

9.  Transport of gabapentin by LAT1 (SLC7A5).

Authors:  David Dickens; Steven D Webb; Svetlana Antonyuk; Athina Giannoudis; Andrew Owen; Steffen Rädisch; S Samar Hasnain; Munir Pirmohamed
Journal:  Biochem Pharmacol       Date:  2013-04-06       Impact factor: 5.858

Review 10.  L-Type amino acid transporter 1 as a target for drug delivery.

Authors:  Elena Puris; Mikko Gynther; Seppo Auriola; Kristiina M Huttunen
Journal:  Pharm Res       Date:  2020-05-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.